Ofev’s reimbursement has been in limbo for 8 years. Will it be different this time?
The stalled health insurance coverage of Ofev (nintedanib), a treatment for the rare and incurable disease pulmonary fibrosis, is drawing renewed attention to whether to end its lengthy process. The drug is also expected to be on the agenda for next month…